Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Current Leases (2021 - 2025)

Indivior Pharmaceuticals has reported Current Leases over the past 5 years, most recently at $10.0 million for Q4 2025.

  • Quarterly results put Current Leases at $10.0 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $10.0 million (changed 0.0% YoY), and the annual figure for FY2025 was $10.0 million, changed 0.0%.
  • Current Leases for Q4 2025 was $10.0 million at Indivior Pharmaceuticals, roughly flat from $10.0 million in the prior quarter.
  • Over the last five years, Current Leases for INDV hit a ceiling of $11.0 million in Q1 2025 and a floor of $8.0 million in Q4 2021.
  • Median Current Leases over the past 5 years was $10.0 million (2024), compared with a mean of $9.6 million.
  • Biggest five-year swings in Current Leases: changed 0.0% in 2022 and later grew 12.5% in 2023.
  • Indivior Pharmaceuticals' Current Leases stood at $8.0 million in 2021, then changed by 0.0% to $8.0 million in 2022, then grew by 12.5% to $9.0 million in 2023, then increased by 11.11% to $10.0 million in 2024, then changed by 0.0% to $10.0 million in 2025.
  • The last three reported values for Current Leases were $10.0 million (Q4 2025), $10.0 million (Q3 2025), and $11.0 million (Q2 2025) per Business Quant data.